164 related articles for article (PubMed ID: 33867147)
21. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V
Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826
[TBL] [Abstract][Full Text] [Related]
23. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
24. Crosstalk between PKCα and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium.
Hsu AH; Lum MA; Shim KS; Frederick PJ; Morrison CD; Chen B; Lele SM; Sheinin YM; Daikoku T; Dey SK; Leone G; Black AR; Black JD
Cell Rep; 2018 Jul; 24(3):655-669. PubMed ID: 30021163
[TBL] [Abstract][Full Text] [Related]
25. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
26. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
[TBL] [Abstract][Full Text] [Related]
27. Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
Wang J; Okkeri J; Pavic K; Wang Z; Kauko O; Halonen T; Sarek G; Ojala PM; Rao Z; Xu W; Westermarck J
EMBO Rep; 2017 Mar; 18(3):437-450. PubMed ID: 28174209
[TBL] [Abstract][Full Text] [Related]
28. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
29. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
30. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
31. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
[TBL] [Abstract][Full Text] [Related]
32. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
[TBL] [Abstract][Full Text] [Related]
33. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
[TBL] [Abstract][Full Text] [Related]
34. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
35. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
36. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Fambrini M; Petraglia F; Pillozzi S; Noci I
Oncol Rep; 2019 Mar; 41(3):1560-1574. PubMed ID: 30569174
[TBL] [Abstract][Full Text] [Related]
37. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.
Joshi A; Miller C; Baker SJ; Ellenson LH
Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082
[TBL] [Abstract][Full Text] [Related]
38. Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D; Abbasi Asbagh L; Derua R; Hubert A; Schrauwen S; Hoorne Y; Amant F; Waelkens E; Sablina A; Janssens V
Cancer Res; 2016 Oct; 76(19):5719-5731. PubMed ID: 27485451
[TBL] [Abstract][Full Text] [Related]
39. Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes.
Li N; Abe S; Kurata M; Abe-Suzuki S; Onishi I; Kirimura S; Murayama T; Hidaka M; Kawano F; Kitagawa M
Pathol Oncol Res; 2014 Apr; 20(2):399-407. PubMed ID: 24163288
[TBL] [Abstract][Full Text] [Related]
40. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
